<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892616</url>
  </required_header>
  <id_info>
    <org_study_id>1402-0010</org_study_id>
    <secondary_id>2018-003603-19</secondary_id>
    <nct_id>NCT03892616</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood</brief_title>
  <official_title>Relative Bioavailability and Food Effect of a Single Dose of Different Solid Formulations of BI 1358894 Compared to a Single Dose of the Reference Tablet Formulation of BI 1358894 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Single-dose, Randomised, Incomplete Blocks Crossover Design Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to investigate the relative bioavailability of a single
      dose of BI 1358894 administered as tablet formulation 2 (TF2a, TF2b) under fasted conditions
      compared with the tablet formulation 1 (TF1) of BI 1358894 under fed conditions following
      oral administration and to investigate the effect of food on the exposure with TF2 (TF2a,
      TF2b).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>Up to 312 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>Up to 312 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 312 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 h)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A - B - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D - A - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E - B - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C - A - D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A - E - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E - D - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - C - D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C - E - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - D - E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D - C - E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C - B - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A - E - D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894 (B)</intervention_name>
    <description>Tablet formulation 2 (TF2a), fed</description>
    <arm_group_label>A - B - C</arm_group_label>
    <arm_group_label>B - C - D</arm_group_label>
    <arm_group_label>B - D - E</arm_group_label>
    <arm_group_label>C - B - A</arm_group_label>
    <arm_group_label>C - E - B</arm_group_label>
    <arm_group_label>D - A - B</arm_group_label>
    <arm_group_label>E - B - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894 (C)</intervention_name>
    <description>Tablet formulation 2 (TF2a), fasted</description>
    <arm_group_label>A - B - C</arm_group_label>
    <arm_group_label>A - E - C</arm_group_label>
    <arm_group_label>B - C - D</arm_group_label>
    <arm_group_label>C - A - D</arm_group_label>
    <arm_group_label>C - B - A</arm_group_label>
    <arm_group_label>C - E - B</arm_group_label>
    <arm_group_label>D - C - E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894 (D)</intervention_name>
    <description>Tablet formulation 2 (TF2b), fed</description>
    <arm_group_label>A - E - D</arm_group_label>
    <arm_group_label>B - C - D</arm_group_label>
    <arm_group_label>B - D - E</arm_group_label>
    <arm_group_label>C - A - D</arm_group_label>
    <arm_group_label>D - A - B</arm_group_label>
    <arm_group_label>D - C - E</arm_group_label>
    <arm_group_label>E - D - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894 (E)</intervention_name>
    <description>Tablet formulation 2 (TF2b), fasted</description>
    <arm_group_label>A - E - C</arm_group_label>
    <arm_group_label>A - E - D</arm_group_label>
    <arm_group_label>B - D - E</arm_group_label>
    <arm_group_label>C - E - B</arm_group_label>
    <arm_group_label>D - C - E</arm_group_label>
    <arm_group_label>E - B - A</arm_group_label>
    <arm_group_label>E - D - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894 (A)</intervention_name>
    <description>Tablet formulation 1 (TF1), fed</description>
    <arm_group_label>A - B - C</arm_group_label>
    <arm_group_label>A - E - C</arm_group_label>
    <arm_group_label>A - E - D</arm_group_label>
    <arm_group_label>C - A - D</arm_group_label>
    <arm_group_label>C - B - A</arm_group_label>
    <arm_group_label>D - A - B</arm_group_label>
    <arm_group_label>E - B - A</arm_group_label>
    <arm_group_label>E - D - A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects according to the assessment of the investigator, as based on a
             complete medical history including a physical examination, vital signs (Blood pressure
             (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory
             tests.

          -  Age of 18 to 50 years (inclusive)

          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)

          -  Signed and dated written informed consent prior to admission to the study, in
             accordance with Good Clinical Practice (GCP) and local legislation

          -  Male subjects who meet any of the following criteria from at least 30 days before the
             first administration of trial medication until 30 days after trial completion:

               -  Use of adequate contraception of the female partner, e.g. any of the following
                  methods plus condom: implants, injectables, combined oral or vaginal
                  contraceptives, intrauterine device (IUD) that started at least 2 months prior to
                  first study drug administration, or barrier method (e.g. diaphragm with
                  spermicide)

               -  Sexually abstinent

               -  A vasectomy performed at least 1 year prior to screening (with medical assessment
                  of the surgical success)

               -  Surgically sterilised female partner (including hysterectomy, bilateral tubal
                  occlusion or bilateral oophorectomy)

        Exclusion Criteria:

          -  Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR)
             or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant
             by the investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 50 to 90 bpm

          -  C-Reactive Protein (CRP) &gt; upper limit of normal (ULN), erythrocyte sedimentation rate
             (ESR) â‰¥15 millimeters/h, liver or kidney parameter above ULN, or any other laboratory
             value outside the reference range that the investigator considers to be of clinical
             relevance

          -  Any evidence of a concomitant disease assessed as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere
             with the pharmacokinetics of the trial medication (except appendectomy and simple
             hernia repair)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Use of drugs within 30 days of planned administration of trial medication that might
             reasonably influence the results of the trial (including drugs that cause QT/QTc
             interval prolongation)

          -  Intake of an investigational drug in another clinical trial within 60 days of planned
             administration of investigational drug in the current trial, or concurrent
             participation in another clinical trial in which investigational drug is administered

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking on specified trial days

          -  Alcohol abuse (consumption of more than 30 g per day)

          -  Drug abuse or positive drug screening

          -  Blood donation of more than 100 mL within 30 days of planned administration of trial
             medication or intended blood donation during the trial

          -  Intention to perform excessive physical activities within one week prior to the
             administration of trial medication or during the trial

          -  Inability to comply with the dietary regimen of the trial site

          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are
             repeatedly greater than 450 ms) or any other relevant ECG finding at screening

          -  A history of additional risk factors for Torsade de Pointes (such as heart failure,
             hypokalaemia, or family history of Long QT Syndrome)

          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,
             because the subject is not considered able to understand and comply with study
             requirements, or has a condition that would not allow safe participation in the study

          -  Any lifetime history of suicidal behaviour (i.e. actual attempt, interrupted attempt,
             aborted attempt, or preparatory acts or behaviour)

          -  Any suicidal ideation of type 2 to 5 on the Columbia Suicidal Severity Rating scale
             (C-SSRS) in the past 12 months (i.e. active suicidal thought, active suicidal thought
             with method, active suicidal thought with intent but without specific plan, or active
             suicidal thought with plan and intent)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

